Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Eye drops study fails to meet endpoint, Oculis stock price plummets

Eye drops study fails to meet endpoint, Oculis stock price plummets

华尔街见闻华尔街见闻2026/05/29 22:12
Show original
Previously, the company stated that its developed OCS-01 eye drops for the treatment of diabetic macular edema (DME) patients failed to meet the primary endpoint in research. In two Phase 3 clinical trials, the main endpoint—the mean change in best corrected visual acuity (BCVA) from baseline to week 52—was not reached. The company plans not to proceed with the U.S. Food and Drug Administration (FDA) submission for OCS-01 in the indication of diabetic macular edema (DME). Going forward, the company will focus its research and development efforts and financial resources on the ongoing Privosegtor PIONEER clinical registration program for optic neuropathy, as well as the PREDICT-1 clinical registration trial for Licaminlimab in treating dry eye disease. The existing cash flow reserves are expected to support the company's operations until the second half of 2029.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

New York gold prices rose on the 8th

新浪财经•2026/10/09 01:36

BUZZ - After the turmoil of Firmus' initial public offering, Australia's Maas Group shares plunged nearly 30% this week

October 9 - ** Shares of Australian Maas Group (MGH.AX) have fallen more than 27% so far this week and are set for their worst weekly performance if the downward trend continues. ** On Thursday, media reported that Firmus, backed by Nvidia, might reduce the size of its AUD 5 billion Australian IPO (link), sparking investor concerns and leading to a 30% plunge in shares of construction services provider MGH. ** MGH holds a 3.2% stake in this AI data center operator. ** MGH suspended trading on Friday (link), pending an announcement related to Firmus. Firmus has shelved its AUD 5 billion listing plan due to market volatility and conditions. ** Before the suspension, MGH's shares had already fallen over 8% this year. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. This automated translation may contain inaccuracies or omit the desired context; Reuters does not guarantee the accuracy of automated translations and provides them solely for reader convenience. Reuters accepts no liability for any harm or loss caused by the use of automated translations.)

路透社•2026/10/09 01:26

Apple to launch dual products in October: First touch-screen MacBook and new iPad mini to debut simultaneously

Apple is planning to hold its second product launch event of the month around October 27, where it will introduce its first-ever touchscreen MacBook Pro (featuring an OLED display and the “Dynamic Island” interface), a new iPad mini (also upgraded with OLED and a repositioned camera), as well as a 14-inch MacBook Pro and iMac powered by the M6 chip. These are the first major products overseen by the new CEO, John Ternus.

华尔街见闻•2026/10/09 01:01

BUZZ - Driven by active trading, the Australian Securities Exchange (ASX) is on track for its best week in two months

October 9 – The stock price of ASX ASX.AX, the operator of the Australian Securities Exchange, has risen more than 3.8% so far this week, on track for its best weekly performance since early August. On Thursday, Citi raised its annual earnings per share (EPS) forecast for ASX by 2%, citing continued strong trading activity. On Friday, the stock was up as much as 0.3% to 60.79 AUD. Citi also holds a positive view of ASX’s new CEO, Anthony Attia, agreeing with his approach of bringing in external talent and modernizing technology. Including the latest gain, the stock is up 18% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Since automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of the translation. The automated translation is provided solely for the convenience of readers, and Reuters accepts no liability for any damage or loss arising from the use of the automated translation.)

路透社•2026/10/09 00:56